AG2011V048USA 8369714 99000001 Docto Account Address Cit St Zip Requisition Collection Date Date Receied Repot Date SpecimenType Customer Re Patient DOB Patient Gende SSN ID: 373878
Download Pdf The PPT/PDF document "22 Morgan | Ivine | C 92618 | ph: 888.32..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
AG2011V048USA 22 Morgan | Ivine | C 92618 | ph: 888.321.2732 | fa: 866.756.754customercare@agendia.com | ww.agendia.com 8369714 / 99000001 Docto: Account Address Cit, St., Zip Requisition # Collection Date Date Receied Repot Date SpecimenType Customer Re. Patient DOB Patient # Gende: SSN Molecular Subtyping Test Result Assay Description Sign O Gene expression analysis has con rmed the heterogeneity of breast cancer, revealing it to be a disease with intrinsic subgroups that can be uncovered by genomic pro ling.1The BluePrint molecular subtyping pro le was designed to distinguish the Basal-type, Luminal-type and ERBB2-type (HER2/neu positive) intrinsic subgroups of tumors. 2 The BluePrint signature determines the RNA levels of 80 genes that best discriminate among these three distinctive subtypes. Tumors from a cohort of 295 patients were used for the development of gene expression pro les speci c for the Basal-type, Luminal-type and ERBB2-type breast cancers. Using state of the art bioinformatics tools, Agendiaidenti edgenes was reached with a set of80genes.Next,anearest-centroidclassi cationprocedureutilizingthe80-genepro lewasdeelopedthatmostaccuatelyclassi edthebreastcancer molecular subtypes on all samples. Based on the analytical performance of BluePrint, the reliability of the measurement is 99.2%. The BluePrint molecular subtyping proe was subsequently validated on 374 independent samples and demonstrated high concordance with the subgroups (excluding normal-like) described by Perou et al.1,2 References CUSOMER SPECIMEN PATIENTPage 1 of 1Tumor Cell Pecentage: 0%(1)Pe Pathology/Additional Comments:This sample is created during the test procedure of the Agenda Report Generator. Unittest: test_107_BP_US_LUMINAL_1_AD8D7A29-C0BC-22A9- Chynel . Henning, MD, PhD, ASC, FCAP Pathologist Laboratoy DirectorLuminal-typebreastcancersarechaacterizedbygeneexpressionofluminalepithelialcellsthatlinethebreastductsandglands.TheLuminal-typecancers aretypicallyhormonereceptorpositvetumorsandthereforeresponsvetohormonaltheay.ALuminal-typemolecularsubtypingresultmeansthatthetumor phenotypemostcloselyresemblestheLuminal-typeintrinsicsubtype.Patientsclassi edasMammaPrint® 70-genesignature“LwRisk”andLuminal-typecanbe expectedtohveaclinicalcoursesimilartoluminalA,usuallytreatedwithhormonaltheay,whereasthosewithaMammaPrint“HighRisk”andLuminal-type, a clinical course similar to luminal B patients ho usually bene t from more aggressve treatment hih my include hemotheay. Luminal-type